Collegium Pharmaceutical to Buy AZSTARYS for $650M, Expanding ADHD Franchise Through 2037 [Yahoo! Finance]
Collegium Pharmaceutical, Inc. (COLL)
Last collegium pharmaceutical, inc. earnings: 2/27 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.collegiumpharma.com
Company Research
Source: Yahoo! Finance
Collegium Pharmaceutical (NASDAQ:COLL) outlined plans to acquire the ADHD drug AZSTARYS and related corporate subsidiaries from Corium Therapeutics, a transaction the company said would add a second commercial-stage ADHD product alongside Jornay PM and extend the durability of its ADHD revenue base. Transaction terms and timing On the investor call, President and CEO Vikram Karnani said Collegium plans to pay $650 million in cash for AZSTARYS and the relevant subsidiaries. Corium Therapeutics shareholders may also receive up to $135 million in contingent payments tied to certain sales and/or regulatory milestones. ? Dollar Tree Planted the Seeds for Triple-Digit Gains in Q4 Collegium expects to fund the purchase with a combination of cash on hand and $300 million from its delayed-draw term loan that is part of a syndicated financing facility announced in December 2025. Karnani said the interest rate upon closing is expected to be SOFR plus 325 basis points , within a range of
Show less
Read more
Impact Snapshot
Event Time:
COLL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COLL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COLL alerts
High impacting Collegium Pharmaceutical, Inc. news events
Weekly update
A roundup of the hottest topics
COLL
News
- Collegium Pharmaceutical, Inc. (COLL) Discusses Acquisition of AZSTARYS to Expand ADHD Portfolio and Accelerate Growth Transcript [Seeking Alpha]Seeking Alpha
- Collegium to Acquire AZSTARYS® from Corium Therapeutics, Strengthening Position in ADHD and Accelerating Growth TrajectoryGlobeNewswire
- Collegium Pharmaceutical touts record 2025, sees JORNAY PM driving 2026 growth at Barclays Miami Conference [Yahoo! Finance]Yahoo! Finance
- A Look At Collegium Pharmaceutical (COLL) Valuation After Recent Share Price Pressure [Yahoo! Finance]Yahoo! Finance
- Collegium Pharmaceutical (COLL) Surged Following Record Quarterly Results [Yahoo! Finance]Yahoo! Finance
COLL
Earnings
- 2/26/26 - Beat
COLL
Sec Filings
- 3/19/26 - Form 8-K
- 3/18/26 - Form 144
- 3/11/26 - Form 4
- COLL's page on the SEC website